Proxima vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI drug discovery for protein-protein interactions; raised $80M seed from DCVC and NVIDIA (Jan 2026); oncology and neurodegeneration focus; opens class of previously undruggable targets
About
Proxima is an AI-driven drug discovery company focused on proteins that control critical biological interactions — specifically targeting protein-protein interactions (PPIs) that have historically been considered undruggable. Founded by researchers with backgrounds in structural biology, machine learning, and medicinal chemistry, Proxima uses AI to design novel therapeutics that can modulate these complex binding interfaces, opening up a vast new class of drug targets for conditions ranging from cancer to neurodegeneration.\n\nThe company's platform integrates protein structure prediction, generative molecular design, and experimental validation in a tightly coupled loop. By leveraging AI models trained on structural and interaction data, Proxima can propose drug candidates targeting previously inaccessible sites on proteins. This approach is particularly relevant for oncology and immunology, where many of the most important biological pathways are mediated by protein complexes that small molecules have struggled to disrupt.\n\nProxima raised an $80M seed round backed by DCVC and NVIDIA in January 2026, one of the largest seed rounds in biotech history. NVIDIA's involvement underscores the computational intensity of the platform and the strategic value of GPU infrastructure partnerships in AI drug discovery. The company is pre-clinical but is building a pipeline of candidates targeting high-value undruggable proteins, with the $80M runway intended to advance multiple programs toward IND filings.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.